Glibenclamide, also known as glyburide, is a sulfonylurea antidiabetic agent used primarily in the management of type 2 diabetes mellitus. It acts by stimulating the release of insulin from the beta cells of the pancreas, thereby lowering blood glucose levels. This compound is indicated when diet and exercise are insufficient for glycemic control. As an active pharmaceutical ingredient (API), it is typically administered orally in tablet form, once or twice daily as prescribed. Glibenclamide improves glycemic control, reduces the risk of diabetic complications, and is often combined with other antidiabetic agents. Caution is advised due to the risk of hypoglycemia, particularly in elderly patients, those with renal or hepatic impairment, or when used with insulin or other hypoglycemic agents. Chemically, it is 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide, with applications in pharmaceutical manufacturing and research.